ElectroCore's Shares Are Trading Higher After Australia Ok'd Vagus Nerve Stimulator For Headaches


The Australian Therapeutic Goods Administration has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products, including a non-invasive vagus nerve stimulator (nVNS) for primary headache disorders.

  • Concurrently, the company has entered into an agreement with Medistar2 PTY Limited, whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire nVNS in Australia.
  • The initial term of the agreement is three years.
  • Medistar, an independent medical device distributor, will officially launch the gammaCore Sapphire at the 2021 ANZHS Headache Annual Scientific Meeting, held on March 13-14. 
  • Last week, the company completed enrollment in a study evaluating the effect of nVNS on respiratory symptoms due to COVID-19.
  • Price Action: ECOR shares surged 58% at $3.43 in premarket trading on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksContractsFDAGeneralAustralian Therapeutic Goods Administrationheadache
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!